Short Interest in Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Increases By 165.9%

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the recipient of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 114,600 shares, an increase of 165.9% from the February 28th total of 43,100 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 331,200 shares, the days-to-cover ratio is currently 0.3 days.

Chugai Pharmaceutical Stock Performance

Shares of OTCMKTS CHGCY traded down $0.25 during trading on Thursday, reaching $23.31. The company had a trading volume of 82,779 shares, compared to its average volume of 200,398. The business’s 50 day moving average price is $23.08 and its 200-day moving average price is $22.90. Chugai Pharmaceutical has a 52 week low of $14.52 and a 52 week high of $27.19. The stock has a market cap of $76.71 billion, a PE ratio of 30.27 and a beta of 0.77.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.18 earnings per share for the quarter. Chugai Pharmaceutical had a return on equity of 21.53% and a net margin of 33.07%. Equities analysts anticipate that Chugai Pharmaceutical will post 0.74 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.